FENC

$7.76

Post-MarketAs of Mar 17, 8:00 PM UTC

Fennec Pharmaceuticals Inc.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

MT Newswires
Mar 17, 2026

B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement

B. Riley reiterated its buy rating on the shares of Fennec Pharmaceuticals (FRX.TO, FENC) and its US

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Mar 16, 2026

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year

This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue

Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.